Therapy Detail

Therapy Name Glesatinib + Erlotinib
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Erlotinib Tarceva CP358774 EGFR Inhibitor (Pan) 38 EGFR Inhibitor 1st gen 3 Tarceva (erlotinib) is a first-generation EGFR inhibitor, which is FDA approved for non-small cell lung carcinoma patients with EGFR exon 19 deletions and/or EGFR L858R and in combination with gemcitabine for patients with advanced pancreatic cancer (; PMID: 25302162).
Glesatinib MGCD265 AXL Inhibitor 24 MET Inhibitor 50 RON Inhibitor 10 VEGFR Inhibitor (Pan) 29 Glesatinib (MGCD265) inhibits several tyrosine kinases including MET, MST1R (RON), and AXL, as well as VEGFR1-3, and TIE2, which may result in decreased tumor growth (PMID: 25806189, PMID: 26555154).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown gastroesophageal junction adenocarcinoma not applicable Glesatinib + Erlotinib Phase I Actionable In a Phase I trial, 38% (3/8) of patients with gastroesophageal cancer remained on study for approximately 12-26 cycles with Glesatinib (MGCD265) and Tarceva (erlotinib) combination therapy (J Clin Oncol 30, 2012 (suppl; abstr e13602)). detail...
Unknown unknown Advanced Solid Tumor not applicable Glesatinib + Erlotinib Phase I Actionable In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination therapy demonstrated safety and preliminary clinical efficacy, resulted in partial response in 1 patient, and stable disease for 6 cycles or more in 16% (7/45) of patients with advanced solid tumors (J Clin Oncol 30, 2012 (suppl; abstr e13602)). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00975767 Phase Ib/II Docetaxel + Glesatinib Glesatinib + Erlotinib A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer Terminated